Though safe, nilotinib does not show promise for benefit for Parkinson's disease
(Northwestern University) The Nilotinib in Parkinson's Disease (NILO-PD) study showed that nilotinib, an FDA-approved treatment for chronic myelogenous leukemia being tested for potential repurposing as a Parkinson's drug, was safe and tolerable in its trial population of 76 participants with moderate to advanced Parkinson's but does not exert a clinically meaningful benefit or biological effect to benefit those with Parkinson's disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2019 Category: International Medicine & Public Health Source Type: news
nilotinib (Tasigna)
Title: nilotinib (Tasigna)Category: MedicationsCreated: 10/14/2011 12:00:00 AMLast Editorial Review: 8/22/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 22, 2019 Category: Cancer & Oncology Source Type: news
Updated Results Show Ongoing Treatment-Free Remission in CML Trial
Updated results from ENESTop show patients with CML remain in treatment-free remission after stopping nilotinib. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
Medical News Today: Parkinson's: Study reveals how cancer drug reduces toxic protein in brain
An analysis of trial results reveals the mechanism through which the cancer drug nilotinib increases brain dopamine in people with Parkinson's disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 13, 2019 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news
Parkinson's: Study reveals how cancer drug reduces toxic protein in brain
An analysis of trial results reveals the mechanism through which the cancer drug nilotinib increases brain dopamine in people with Parkinson's disease. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - March 13, 2019 Category: Neurology Tags: Parkinson's Disease Source Type: news
Researchers decode how cancer drug works in brains of Parkinson's disease patients
(Georgetown University Medical Center) The first arm of a phase II clinical trial by a research team at Georgetown University Medical Center testing the use of nilotinib in patients with Parkinson's disease demonstrates precisely how the agent increases levels of dopamine in the brains of study participants. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 12, 2019 Category: International Medicine & Public Health Source Type: news
Genoptix Launches FDA-Authorized BCR-ABL MRDx(R) TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna(R) (nilotinib)
CARLSBAD, Calif., Sept. 4, 2018 -- (Healthcare Sales & Marketing Network) -- Genoptix, Inc., a leading oncology diagnostic laboratory, announces the immediate availability of a proprietary, FDA-authorized BCR-ABL MRDx® TFR Monitoring Test for patients... Diagnostics, Oncology, Product Launch Genoptix, BCR-ABL MRDx, TFR Monitoring Test, chronic myeloid leukemia, Tasigna (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 4, 2018 Category: Pharmaceuticals Source Type: news
FDA OKs Tasigna for Rare Leukemia in Children
(MedPage Today) -- Approved in first- and second-line settings (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 22, 2018 Category: American Health Source Type: news
Novartis Drug Tasigna Approved by FDA to Treat Children with Rare Form of Leukemia
Basel, March 22, 2018 - Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 22, 2018 Category: Drugs & Pharmacology Source Type: news
URMC Investigating New Parkinson's Drug
The University of Rochester Medical Center Clinical Trials Coordination Center (CTCC) has been tapped to help lead a clinical trial for a potential new treatment for Parkinson ’s disease. The study will evaluate nilotinib, a drug currently used to treat leukemia that has shown promise in early studies in people with Parkinson’s disease. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - March 1, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news
Treatment - Free Remission Feasible After Nilotinib in CML
For patients with chronic myeloid leukemia in chronic phase, TFR is feasible after second - line treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 26, 2018 Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news
Treatment-free Remission of CML Feasible for Some After Second-line Nilotinib Treatment-free Remission of CML Feasible for Some After Second-line Nilotinib
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
FDA Updates Labeling for Nilotinib: Treatment Can Be Stopped FDA Updates Labeling for Nilotinib: Treatment Can Be Stopped
The FDA has updated labeling for nilotinib, specifying that for certain patients in long-term remission, treatment can be stopped.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response
(Source: Food and Drug Administration)
Source: Food and Drug Administration - December 22, 2017 Category: American Health Source Type: news
FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response
The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinue the drug in certain patients. Tasigna, first approved by the FDA in 2007, is indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). (Source: World Pharma News)
Source: World Pharma News - December 22, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
